![glp-1-receptoragonister GLP-1 for Diabetes vs GLP-1 for Weight Loss: What's Changing for Patients and Pharmacies? glp-1_analogs [TUSOM | Pharmwiki]](https://serv-u-pharmacy.com/wp-content/uploads/2026/03/glp1_receptor_agonists_function-e1774346770207.jpeg)
glp-1-receptoragonister GLP-1 for Diabetes vs GLP-1 for Weight Loss: What's Changing for Patients and Pharmacies? glp-1_analogs [TUSOM | Pharmwiki]
Description
doi: 10.1007/s11883-022-01062-2 [DOI] [PubMed] [Google Scholar] 144
![glp-1-receptoragonister GLP-1 for Diabetes vs GLP-1 for Weight Loss: What's Changing for Patients and Pharmacies? glp-1_analogs [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1.png?w=600&tok=baf39c)
Without these lifestyle changes, weight loss may not stick once medications are tapered down or stopped, highlighting the importance of long-term habits for maintaining health and achieving lasting weight management
![glp-1-receptoragonister GLP-1 for Diabetes vs GLP-1 for Weight Loss: What's Changing for Patients and Pharmacies? glp-1_analogs [TUSOM | Pharmwiki]](https://cdn.sanity.io/images/0vv8moc6/ajmc/ec6da25e8eee698813fc4f1d2d4cd687f61c4c13-4528x2566.jpg)
For example, clinical trials for semaglutide at a 2.4 mg dose showed that 44.2% of participants experienced nausea, compared to 17.4% in the placebo group
![glp-1-receptoragonister GLP-1 for Diabetes vs GLP-1 for Weight Loss: What's Changing for Patients and Pharmacies? glp-1_analogs [TUSOM | Pharmwiki]](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00228-025-03823-9/MediaObjects/228_2025_3823_Fig1_HTML.png)
SLIMMER showed acceptable safety in 664 patients
![glp-1-receptoragonister GLP-1 for Diabetes vs GLP-1 for Weight Loss: What's Changing for Patients and Pharmacies? glp-1_analogs [TUSOM | Pharmwiki]](https://www.mdpi.com/genes/genes-16-01352/article_deploy/html/images/genes-16-01352-g001.png)
